Shawver Laura 4
4 · ARS Pharmaceuticals, Inc. · Filed Jun 26, 2026
Research Summary
AI-generated summary of this filing
ARS Pharmaceuticals (SPRY) Director Laura Shawver Receives Award
What Happened
Laura Shawver, a director of ARS Pharmaceuticals (SPRY), was granted a derivative award of 30,000 shares on June 24, 2026. The award shows an acquisition price of $0.00 (no cash paid at grant). The filing classifies this as a grant/award (derivative instrument) rather than an open-market purchase or sale.
Key Details
- Transaction date: 2026-06-24; filing date: 2026-06-26 (filed within the two-business-day Form 4 window).
- Instrument: Derivative award of 30,000 shares; reported acquisition price $0.00.
- Shares owned after transaction: Not specified in the filing.
- Footnote: The shares subject to the award/option vest in full on the earlier of June 24, 2027 or the date of the issuer’s 2027 annual meeting of stockholders.
- No indication of a Section 16(c) sale, 10b5-1 plan, or tax-withholding sale in this filing.
Context
This is an equity-compensation grant to a director, not an open-market purchase or sale. Such awards are common for executive/director compensation and do not necessarily signal immediate bullish or bearish trading intent since the shares are subject to future vesting. The award does not involve an immediate exercise-and-sell (cashless) event; value will depend on future vesting and the company’s stock price at that time.
Insider Transaction Report
- Award
Stock Option (right to buy)
[F1]2026-06-24+30,000→ 30,000 totalExercise: $10.54Exp: 2036-06-23→ Common Stock (30,000 underlying)
Footnotes (1)
- [F1]The shares subject to the option will vest in full on the earlier of June 24, 2027 or the date of the Issuer's 2027 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors.